About PILA PHARMA
PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.
Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.
FÅ PRESSMEDDELANDEN / GET PRESS RELEASES
News
Kommuniké från årsstämma i Pila Pharma AB 2022
Läs pressmeddelandet (in Swedish) här
(07-June-2022)
We’re delighted to be back at the wonderful Børsen with Dansk Erhverv, Medicon Valley Alliance Øresundsinstituttet next Monday, May 30th to discuss regional success, collaboration, challenges and more! 🟠
(23-May-2022)
Sign up is required (!) – follow along in the link här
(18-May-2022)
Läs pressmeddelandet (in Swedish) här
(09-May-2022)
Late last week Redeye had a brief interview with our CEO, Dorte X. Gram regarding the last quarterly report and recent significant changes and developments in Pila.
Please, find the link to the video (in English) here
(03-May-2022)
Delårsrapport 1 januari – 31 mars 2022
Läs rapporten PDF (in Swedish) här
(26-April-2022)
Läs (in Swedish) här
(05-April-2022)
Årsredovisning för 2021
Läs rapporten PDF (in Swedish) här
(23-March-2022)